Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Melanoma 41Carcinoma, Non-Small-Cell Lung 35Carcinoma, Renal Cell 26Neoplasm Metastasis 19Lung Neoplasms 18Carcinoma, Hepatocellular 15Squamous Cell Carcinoma of Head and Neck 11Colorectal Neoplasms 11Pancreatic Neoplasms 10Neoplasms 9Carcinoma, Transitional Cell 9Multiple Myeloma 8Urinary Bladder Neoplasms 7Small Cell Lung Carcinoma 7Head and Neck Neoplasms 7Breast Neoplasms 7Triple Negative Breast Neoplasms 6Ovarian Neoplasms 6Hodgkin Disease 6Advanced Cancer 6Myelodysplastic Syndromes 5Hematologic Neoplasms 5Brain Neoplasms 5Skin Neoplasms 4Recurrence 4Lymphoma 4Kidney Neoplasms 4Glioblastoma 4Fallopian Tube Neoplasms 4Uveal Melanoma 3

Interventions

rucaparib 1adavosertib 1Radiation 1Platinum 1Nivolumab 1Congresses as Topic 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Endometrioid × Nivolumab × Clear all
NCT03824704 2023-06-12

A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)

pharmaand GmbH

Phase 2 Terminated
1 enrolled 7 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡